Phase 1b study reports early results for subcutaneous tarlatamab in extensive-stage small-cell lung cancer
Science & ClimateWell-covered
|
The Facts
- DeLLphi-308 is a phase 1b study of subcutaneous tarlatamab in previously treated extensive-stage small-cell lung cancer.
- Researchers reported that subcutaneous tarlatamab was well tolerated in DeLLphi-308.
- DeLLphi-308 reported preliminary antitumor activity with subcutaneous tarlatamab.
- The DeLLphi-308 findings were presented at the IASLC 2026 World Conference on Lung Cancer in Seoul.
- DeLLphi-308 is the first study to investigate subcutaneous delivery of tarlatamab.
- Tarlatamab had previously been evaluated through intravenous administration.
- Subcutaneous delivery may improve the convenience of tarlatamab treatment.
Context
What is tarlatamab?
Tarlatamab is a bispecific T-cell engager immunotherapy that has established clinical activity in small-cell lung cancer. News-Medical.net EurekAlert!
Who was studied in DeLLphi-308?
The study enrolled patients with previously treated extensive-stage small-cell lung cancer. News-Medical.net EurekAlert!
Why does the delivery method matter?
The study evaluated giving tarlatamab under the skin instead of intravenously; researchers said this approach may improve convenience and produce delayed, lower peak serum concentrations. News-Medical.net EurekAlert!
Where Left and Right agree
Left and right largely agree on this one.
- What both sides accept
- Both agree subcutaneous tarlatamab looks promising and tolerable in this first trial but needs more evidence before being called a real improvement over IV dosing.
- Where Left and Right differ in emphasis
- Both call for more data before declaring success: one warns against overreading any early trial, the other insists convenience itself is worth rigorously proving.
How left and right read it
What matters here is not getting ahead of the evidence: a first look at any new delivery method deserves scrutiny before it gets treated as a settled improvement. Being well tolerated and showing preliminary antitumor activity in this first study of subcutaneous delivery is a reason to keep testing, not a verdict that the shift from intravenous dosing already delivers real benefit or true convenience for patients.
Convenience is not a frill; it is control a patient gets back over his own days, which is why reformulating tarlatamab for delivery under the skin rather than by infusion is worth taking seriously. DeLLphi-308 is the first study to test that route, and it reported the drug was well tolerated with preliminary antitumor activity. Early, yes. So finish the work — and judge it on evidence, not on the assumption that easier delivery matters less than the molecule itself.
The receipts — 26 sources
Independent coverage (26)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.